ReproCELL Incorporated announced that its PMDA face-to-face consultation on the clinical trial plan for GPC-1 CAR-T therapy had concluded. The announcement was made on 19 October 2026.
ReproCELL Incorporated announced that its PMDA face-to-face consultation on the clinical trial plan for GPC-1 CAR-T therapy had concluded. The announcement reports that the company obtained face-to-face advice from PMDA in the course of an application or review process.
The announcement was made on 19 October 2026 and is worded as a notice of the completion of the face-to-face consultation. The text does not provide details of any specific future procedures or review schedule.